LiquiPath™ – The world’s first cfDNA-based platform for multi-tissue drug safety monitoring

• The rapid expansion of ADC development is exposing the limitations of traditional approaches to safety assessment and monitoring
• Tissue-of-origin cfDNA provides a new window into treatment-induced injury
• One translational platform can support ADC safety from preclinical studies to patients, and better safety insight enables better ADC development decisions

Speakers:

John Gallon

Programme Lead - Organ Health

Tagomics